Research progress of long non<b>-</b>coding RNA as competitive endogenous RNA and its targeting technology in pancreatic cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

RUAN Wanbai ¹ , LI Junfeng ¹ , YIN Yanmei ¹ , PENG Lei ¹ ,  ZHU Kexiang ²

1. The First Clinical Medical College of Lanzhou University, Lanzhou 730000, P. R. China;
2. Department of General Surgery, The First Hospital of Lanzhou university, Lanzhou 730000, P. R. China;

Corresponding author：

ZHU Kexiang, Email: flexzhu6910@163.com

Keywords：

long non-coding RNA; competitive endogenous RNA; pancreatic cancer; targeted therapy

DOI：

10.7507/1007-9424.202305037

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize the latest research of long non-coding RNA (lncRNA) as competitive endogenous RNA (ceRNA) and its targeting technology in pancreatic cancer, so as to provide new ideas for lncRNA targeted intervention or as an early diagnostic marker of pancreatic cancer. Method The domestic and foreign literature on researches of lncRNA as ceRNA and its targeting technology in the pancreatic cancer was searched and reviewed. Results At present, the growing number of evidences showed that in pathological states such as tumors, the abundance of intracellular lncRNAs was sufficient to trigger ceRNA crosstalk. The lncRNA played a role like “sponge” through the complementary binding of incomplete base of miRNA with miRNA response elements, then adsorbed miRNA, and thus changed the activity and effectiveness of miRNA. It also regulated the expression of downstream target genes. Moreover, a large number of studies had identified that the lncRNA-mediated ceRNA regulatory network, namely lncRNA/miRNA/mRNA axis, played a role in promoting or inhibiting the occurrence and progression of pancreatic cancer through a variety of cellular functions. In addition, many technologies targeting lncRNA, such as small interfering RNA, antisense oligonucleotides, clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9, and small molecule inhibitors, etc. had been widely studied and acquired important results in preclinical research. Conclusions The ceRNA hypothesis is a functional complex composed by non-coding RNAs and mRNAs with non-coding properties, forming a ceRNA network of multi-level and cross-regulatory on the transcriptome. Epigenetic modification and key post-transcriptional regulation of lncRNA have been achieved through ceRNA network mechanism, which has become a successful paradigm for exploring the function of lncRNA. The tumor suppressive and promoting effects and mechanisms of many lncRNAs in the occurrence and development of pancreatic cancer are explored in many studies. Moreover, the continuous progress of targeted lncRNA technology provides conditions for study of lncRNA. LncRNA has a potential to be used as a biomarker for precancerous diagnosis and prognosis of pancreatic cancer.

Citation： RUAN Wanbai, LI Junfeng, YIN Yanmei, PENG Lei, ZHU Kexiang. Research progress of long non-coding RNA as competitive endogenous RNA and its targeting technology in pancreatic cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2023, 30(9): 1111-1118. doi: 10.7507/1007-9424.202305037 Copy

1.	Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin, 2023, 73(1): 17-48.
2.	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
3.	Traub B, Link KH, Kornmann M. Curing pancreatic cancer. Semin Cancer Biol, 2021, 76: 232-246.
4.	Mizrahi JD, Surana R, Valle JW, et al. Pancreatic cancer. Lancet, 2020, 395(10242): 2008-2020.
5.	Cai J, Chen H, Lu M, et al. Advances in the epidemiology of pancreatic cancer: trends, risk factors, screening, and prognosis. Cancer Lett, 2021, 520: 1-11.
6.	Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin, 2021, 71(1): 7-33.
7.	Seyed Hosseini E, Nikkhah A, Sotudeh A, et al. The impact of LncRNA dysregulation on clinicopathology and survival of pancreatic cancer: a systematic review and meta-analysis (PRISMA compliant). Cancer Cell Int, 2021, 21(1): 447. doi: 10.1186/s12935-021-02125-1.
8.	Xu J, Xu J, Liu X, et al. The role of lncRNA-mediated ceRNA regulatory networks in pancreatic cancer. Cell Death Discov, 2022, 8(1): 287. doi: 10.1038/s41420-022-01061-x.
9.	Wang L, Cho KB, Li Y, et al. Long noncoding RNA (lncRNA)-mediated competing endogenous RNA networks provide novel potential biomarkers and therapeutic targets for colorectal cancer. Int J Mol Sci, 2019, 20(22): 5758. doi: 10.3390/ijms20225758.
10.	Salmena L, Poliseno L, Tay Y, et al. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?. Cell, 2011, 146(3): 353-358.
11.	Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell, 2009, 136(2): 215-233.
12.	Yang N, Liu K, Yang M, et al. ceRNAs in cancer: mechanism and functions in a comprehensive regulatory network. J Oncol, 2021, 2021: 4279039. doi: 10.1155/2021/4279039.
13.	Qu J, Li M, Zhong W, et al. Competing endogenous RNA in cancer: a new pattern of gene expression regulation. Int J Clin Exp Med, 2015, 8(10): 17110-17116.
14.	Liu Y, Khan S, Li L, et al. Molecular mechanisms of thyroid cancer: a competing endogenous RNA (ceRNA) point of view. Biomed Pharmacother, 2022, 146: 112251. doi: 10.1016/j.biopha.2021.112251.
15.	Yu XM, Li SJ, Yao ZT, et al. N4-acetylcytidine modification of lncRNA CTC-490G23.2 promotes cancer metastasis through interacting with PTBP1 to increase CD44 alternative splicing. Oncogene, 2023, 42(14): 1101-1116.
16.	Ashrafizadeh M, Rabiee N, Kumar AP, et al. Long noncoding RNAs (lncRNAs) in pancreatic cancer progression. Drug Discov Today, 2022, 27(8): 2181-2198.
17.	Chen S, Guo W, Meng M, et al. LncRNA SNHG1 promotes the progression of pancreatic cancer by regulating FGFR1 expression via competitively binding to miR-497. Front Oncol, 2022, 12: 813850. doi: 10.3389/fonc.2022.813850.
18.	Li N, Yang G, Luo L, et al. lncRNA THAP9-AS1 promotes pancreatic ductal adenocarcinoma growth and leads to a poor clinical outcome via sponging miR-484 and interacting with YAP. Clin Cancer Res, 2020, 26(7): 1736-1748.
19.	Wu Y, Zhu B, Yan Y, et al. Long non-coding RNA SNHG1 stimulates ovarian cancer progression by modulating expression of miR-454 and ZEB1. Mol Oncol, 2021, 15(5): 1584-1596.
20.	Zhang M, Yang L, Hou L, et al. LncRNA SNHG1 promotes tumor progression and cisplatin resistance through epigenetically silencing miR-381 in breast cancer. Bioengineered, 2021, 12(2): 9239-9250.
21.	Meng F, Liu J, Lu T, et al. SNHG1 knockdown upregulates miR-376a and downregulates FOXK1/Snail axis to prevent tumor growth and metastasis in HCC. Mol Ther Oncolytics, 2021, 21: 264-277.
22.	Tan X, Chen WB, Lv DJ, et al. LncRNA SNHG1 and RNA binding protein hnRNPL form a complex and coregulate CDH1 to boost the growth and metastasis of prostate cancer. Cell Death Dis, 2021, 12(2): 138. doi: 10.1038/s41419-021-03413-4.
23.	Zhou D, He S, Zhang D, et al. LINC00857 promotes colorectal cancer progression by sponging miR-150-5p and upregulating HMGB3 (high mobility group box 3) expression. Bioengineered, 2021, 12(2): 12107-12122.
24.	Zhang W, Ji K, Min C, et al. Oncogenic LINC00857 recruits TFAP2C to elevate FAT1 expression in gastric cancer. Cancer Sci, 2023, 114(1): 63-74.
25.	Huang Y, Lin Y, Song X, et al. LINC00857 contributes to proliferation and lymphomagenesis by regulating miR-370-3p/CBX3 axis in diffuse large B-cell lymphoma. Carcinogenesis, 2021, 42(5): 733-741.
26.	Ren X, Liu J, Wang R, et al. Exploring the oncogenic roles of LINC00857 in pan-cancer. Front Pharmacol, 2022, 13: 996686. doi: 10.3389/fphar.2022.996686.
27.	Chen P, Zeng Z, Wang J, et al. Long noncoding RNA LINC00857 promotes pancreatic cancer proliferation and metastasis by regulating the miR-130b/RHOA axis. Cell Death Discov, 2022, 8(1): 198. doi: 10.1038/s41420-022-01008-2.
28.	Li C, Li X, Zhang Y, et al. DSCAM-AS1 promotes cervical carcinoma cell proliferation and invasion via sponging miR-338-3p. Environ Sci Pollut Res Int, 2022, 29(39): 58906-58914.
29.	Wang Y, Zhai S, Xing J, et al. Long noncoding RNA DSCAM-AS1 facilitates proliferation and migration of hemangioma endothelial cells by targeting miR-411-5p/TPD52 axis. Biomed Res Int, 2022, 2022: 8696432. doi: 10.1155/2022/8696432.
30.	Ghafouri-Fard S, Khoshbakht T, Taheri M, et al. A review on the carcinogenic roles of DSCAM-AS1. Front Cell Dev Biol, 2021, 9: 758513. doi: 10.3389/fcell.2021.758513.
31.	Huang X, Wang Z, Hou S, et al. Long non-coding RNA DSCAM-AS1 promotes pancreatic cancer progression via regulating the miR-136-5p/PBX3 axis. Bioengineered, 2022, 13(2): 4153-4165.
32.	Liu Y, Shi M, He X, et al. LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma. J Hematol Oncol, 2022, 15(1): 52. doi: 10.1186/s13045-022-01272-w.
33.	Ma YS, Yang XL, Liu YS, et al. Long non-coding RNA NORAD promotes pancreatic cancer stem cell proliferation and self-renewal by blocking microRNA-202-5p-mediated ANP32E inhibition. J Transl Med, 2021, 19(1): 400. doi: 10.1186/s12967-021-03052-5.
34.	Fang X, Cai Y, Xu Y, et al. Exosome-mediated lncRNA SNHG11 regulates angiogenesis in pancreatic carcinoma through miR-324-3p/VEGFA axis. Cell Biol Int, 2022, 46(1): 106-117.
35.	Wu R, Su Z, Zhao L, et al. Extracellular vesicle-loaded oncogenic lncRNA NEAT1 from adipose-derived mesenchymal stem cells confers gemcitabine resistance in pancreatic cancer via miR-491-5p/Snail/SOCS3 axis. Stem Cells Int, 2023, 2023: 6510571. doi: 10.1155/2023/6510571.
36.	Liu Y, Luo J, Zeng J, et al. Competing endogenous RNA analysis identified lncRNA DSCR9 as a novel prognostic biomarker associated with metastasis and tumor microenvironment in renal cell carcinoma. Oncol Lett, 2023, 26(1): 290. doi: 10.3892/ol.2023.13876.
37.	Li M, Lin C, Cai Z. Downregulation of the long noncoding RNA DSCR9 (Down syndrome critical region 9) delays breast cancer progression by modulating microRNA-504-5p-dependent G protein-coupled receptor 65. Hum Cell. 2023;36(4): 1516-1534.
38.	Huang H, Li X, Zhang X, et al. DSCR9/miR-21-5p axis inhibits pancreatic cancer proliferation and resistance to gemcitabine via BTG2 signaling. Acta Biochim Biophys Sin (Shanghai), 2022, 54(12): 1775-1788.
39.	Shi Y, Zhang DD, Liu JB, et al. Comprehensive analysis to identify DLEU2L/TAOK1 axis as a prognostic biomarker in hepatocellular carcinoma. Mol Ther Nucleic Acids, 2021, 23: 702-718.
40.	Xu F, Wu H, Xiong J, et al. Long non-coding RNA DLEU2L targets miR-210-3p to suppress gemcitabine resistance in pancreatic cancer cells via BRCA2 regulation. Front Mol Biosci, 2021, 8: 645365. doi: 10.3389/fmolb.2021.645365.
41.	Guz M, Jeleniewicz W, Cybulski M, et al. Serum miR-210-3p can be used to differentiate between patients with pancreatic ductal adenocarcinoma and chronic pancreatitis. Biomed Rep, 2021, 14(1): 10. doi: 10.3892/br.2020.1386.
42.	Yang Z, Zhao N, Cui J, et al. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210. Cell Oncol (Dordr), 2020, 43(1): 123-136.
43.	Pan S, Shen M, Zhou M, et al. Long noncoding RNA LINC01111 suppresses pancreatic cancer aggressiveness by regulating DUSP1 expression via microRNA-3924. Cell Death Dis, 2019, 10(12): 883. doi: 10.1038/s41419-019-2123-y.
44.	Li K, Han H, Gu W, et al. Long non-coding RNA LINC01963 inhibits progression of pancreatic carcinoma by targeting miR-641/TMEFF2. Biomed Pharmacother, 2020, 129: 110346. doi: 10.1016/j.biopha.2020.110346.
45.	Li X, Zhou S, Fan T, et al. LncRNA DGCR 5/miR-27a-3p/BNIP3 promotes cell apoptosis in pancreatic cancer by regulating the p38 MAPK pathway. Int J Mol Med, 2020, 46(2): 729-739.
46.	Gao ZQ, Wang JF, Chen DH, et al. Long non-coding RNA GAS5 suppresses pancreatic cancer metastasis through modulating miR-32-5p/PTEN axis. Cell Biosci, 2017, 7: 66. doi: 10.1186/s13578-017-0192-0.
47.	Kara G, Calin GA, Ozpolat B. RNAi-based therapeutics and tumor targeted delivery in cancer. Adv Drug Deliv Rev, 2022, 182: 114113. doi: 10.1016/j.addr.2022.114113.
48.	Liang Y, Chen X, Wu Y, et al. LncRNA CASC9 promotes esophageal squamous cell carcinoma metastasis through upregulating LAMC2 expression by interacting with the CREB-binding protein. Cell Death Differ, 2018, 25(11): 1980-1995.
49.	Vaidya AM, Sun Z, Ayat N, et al. Systemic delivery of tumor-targeting siRNA nanoparticles against an oncogenic lncRNA facilitates effective triple-negative breast cancer therapy. Bioconjug Chem, 2019, 30(3): 907-919.
50.	Pang H, Ren Y, Li H, et al. LncRNAs linc00311 and AK141205 are identified as new regulators in STAT3-mediated neuropathic pain in bCCI rats. Eur J Pharmacol, 2020, 868: 172880. doi: 10.1016/j.ejphar.2019.172880.
51.	Xu L, Wei B, Hui H, et al. Positive feedback loop of lncRNA LINC01296/miR-598/Twist1 promotes non-small cell lung cancer tumorigenesis. J Cell Physiol, 2019, 234(4): 4563-4571.
52.	Schultheis B, Strumberg D, Kuhlmann J, et al. Safety, efficacy and pharcacokinetics of targeted therapy with the liposomal RNA interference therapeutic Atu027 combined with gemcitabine in patients with pancreatic adenocarcinoma. A randomized phase Ⅰb/Ⅱa study. Cancers (Basel), 2020, 12(11): 3130. doi: 10.3390/cancers12113130.
53.	Zorde-Khvalevsky E, Gabai R, Rachmut IH, et al. Mutant KRAS is a druggable target for pancreatic cancer. Proc Natl Acad Sci USA, 2013, 110(51): 20723-20728.
54.	Adams D, Polydefkis M, González-Duarte A, et al. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurol, 2021, 20(1): 49-59.
55.	Balwani M, Sardh E, Ventura P, et al. Phase 3 Trial of RNAi therapeutic givosiran for acute intermittent porphyria. N Engl J Med, 2020, 382(24): 2289-2301.
56.	Crooke ST, Baker BF, Crooke RM, et al. Antisense technology: an overview and prospectus. Nat Rev Drug Discov, 2021, 20(6): 427-453.
57.	Arun G, Diermeier S, Akerman M, et al. Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss. Genes Dev, 2016, 30(1): 34-51.
58.	Taiana E, Favasuli V, Ronchetti D, et al. Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma. Leukemia, 2020, 34(1): 234-244.
59.	Sutaria DS, Jiang J, Azevedo-Pouly ACP, et al. Expression profiling identifies the noncoding processed transcript of HNRNPU with proliferative properties in pancreatic ductal adenocarcinoma. Noncoding RNA, 2017, 3(3): 24. doi: 10.3390/ncrna3030024.
60.	Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. Science, 2013, 339(6121): 819-823.
61.	Mali P, Yang L, Esvelt KM, et al. RNA-guided human genome engineering via Cas9. Science, 2013, 339(6121): 823-826.
62.	Chen Y, Li Z, Chen X, et al. Long non-coding RNAs: from disease code to drug role. Acta Pharm Sin B, 2021, 11(2): 340-354.
63.	Dorn A, Glaß M, Neu CT, et al. LINC00261 is differentially expressed in pancreatic cancer subtypes and regulates a pro-epithelial cell identity. Cancers (Basel), 2020, 12(5): 1227. doi: 10.3390/cancers12051227.
64.	Guo R, Su Y, Zhang Q, et al. LINC00478-derived novel cytoplasmic lncRNA LacRNA stabilizes PHB2 and suppresses breast cancer metastasis via repressing MYC targets. J Transl Med, 2023, 21(1): 120. doi: 10.1186/s12967-023-03967-1.
65.	Chang KW, Hung WW, Chou CH, et al. LncRNA MIR31HG drives oncogenicity by inhibiting the limb-bud and heart development gene ( LBH) during oral carcinoma. Int J Mol Sci, 2021, 22(16): 8383. doi: 10.3390/ijms22168383.
66.	Boos F, Oo JA, Warwick T, et al. The endothelial-enriched lncRNA LINC00607 mediates angiogenic function. Basic Res Cardiol, 2023, 118(1): 5. doi: 10.1007/s00395-023-00978-3.
67.	Goyal A, Myacheva K, Groß M, et al. Challenges of CRISPR/Cas9 applications for long non-coding RNA genes. Nucleic Acids Res, 2017, 45(3): e12. doi: 10.1093/nar/gkw883.
68.	Ren Y, Wang YF, Zhang J, et al. Targeted design and identification of AC1NOD4Q to block activity of HOTAIR by abrogating the scaffold interaction with EZH2. Clin Epigenetics, 2019, 11(1): 29. doi: 10.1186/s13148-019-0624-2.
69.	Ji D, Hou L, Xie C, et al. Deoxyelephantopin suppresses pancreatic cancer progression in vitro and in vivo by targeting linc00511/miR-370-5p/p21 promoter axis. J Oncol, 2022, 2022: 3855462. doi: 10.1155/2022/3855462.
70.	Matouk I, Raveh E, Ohana P, et al. The increasing complexity of the oncofetal H19 gene locus: functional dissection and therapeutic intervention. Int J Mol Sci, 2013, 14(2): 4298-4316.
71.	Gofrit ON, Benjamin S, Halachmi S, et al. DNA based therapy with diphtheria toxin-A BC-819: a phase 2b marker lesion trial in patients with intermediate risk nonmuscle invasive bladder cancer. J Urol, 2014, 191(6): 1697-1702.
72.	Lavie O, Edelman D, Levy T, et al. A phase 1/2a, dose-escalation, safety, pharmacokinetic, and preliminary efficacy study of intraperitoneal administration of BC-819 (H19-DTA) in subjects with recurrent ovarian/peritoneal cancer. Arch Gynecol Obstet, 2017, 295(3): 751-761.
73.	Hanna N, Ohana P, Konikoff FM, et al. Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of BC-819 in patients with unresectable pancreatic cancer. Cancer Gene Ther, 2012, 19(6): 374-381.

1. Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin, 2023, 73(1): 17-48.
2. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
3. Traub B, Link KH, Kornmann M. Curing pancreatic cancer. Semin Cancer Biol, 2021, 76: 232-246.
4. Mizrahi JD, Surana R, Valle JW, et al. Pancreatic cancer. Lancet, 2020, 395(10242): 2008-2020.
5. Cai J, Chen H, Lu M, et al. Advances in the epidemiology of pancreatic cancer: trends, risk factors, screening, and prognosis. Cancer Lett, 2021, 520: 1-11.
6. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin, 2021, 71(1): 7-33.
7. Seyed Hosseini E, Nikkhah A, Sotudeh A, et al. The impact of LncRNA dysregulation on clinicopathology and survival of pancreatic cancer: a systematic review and meta-analysis (PRISMA compliant). Cancer Cell Int, 2021, 21(1): 447. doi: 10.1186/s12935-021-02125-1.
8. Xu J, Xu J, Liu X, et al. The role of lncRNA-mediated ceRNA regulatory networks in pancreatic cancer. Cell Death Discov, 2022, 8(1): 287. doi: 10.1038/s41420-022-01061-x.
9. Wang L, Cho KB, Li Y, et al. Long noncoding RNA (lncRNA)-mediated competing endogenous RNA networks provide novel potential biomarkers and therapeutic targets for colorectal cancer. Int J Mol Sci, 2019, 20(22): 5758. doi: 10.3390/ijms20225758.
10. Salmena L, Poliseno L, Tay Y, et al. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?. Cell, 2011, 146(3): 353-358.
11. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell, 2009, 136(2): 215-233.
12. Yang N, Liu K, Yang M, et al. ceRNAs in cancer: mechanism and functions in a comprehensive regulatory network. J Oncol, 2021, 2021: 4279039. doi: 10.1155/2021/4279039.
13. Qu J, Li M, Zhong W, et al. Competing endogenous RNA in cancer: a new pattern of gene expression regulation. Int J Clin Exp Med, 2015, 8(10): 17110-17116.
14. Liu Y, Khan S, Li L, et al. Molecular mechanisms of thyroid cancer: a competing endogenous RNA (ceRNA) point of view. Biomed Pharmacother, 2022, 146: 112251. doi: 10.1016/j.biopha.2021.112251.
15. Yu XM, Li SJ, Yao ZT, et al. N4-acetylcytidine modification of lncRNA CTC-490G23.2 promotes cancer metastasis through interacting with PTBP1 to increase CD44 alternative splicing. Oncogene, 2023, 42(14): 1101-1116.
16. Ashrafizadeh M, Rabiee N, Kumar AP, et al. Long noncoding RNAs (lncRNAs) in pancreatic cancer progression. Drug Discov Today, 2022, 27(8): 2181-2198.
17. Chen S, Guo W, Meng M, et al. LncRNA SNHG1 promotes the progression of pancreatic cancer by regulating FGFR1 expression via competitively binding to miR-497. Front Oncol, 2022, 12: 813850. doi: 10.3389/fonc.2022.813850.
18. Li N, Yang G, Luo L, et al. lncRNA THAP9-AS1 promotes pancreatic ductal adenocarcinoma growth and leads to a poor clinical outcome via sponging miR-484 and interacting with YAP. Clin Cancer Res, 2020, 26(7): 1736-1748.
19. Wu Y, Zhu B, Yan Y, et al. Long non-coding RNA SNHG1 stimulates ovarian cancer progression by modulating expression of miR-454 and ZEB1. Mol Oncol, 2021, 15(5): 1584-1596.
20. Zhang M, Yang L, Hou L, et al. LncRNA SNHG1 promotes tumor progression and cisplatin resistance through epigenetically silencing miR-381 in breast cancer. Bioengineered, 2021, 12(2): 9239-9250.
21. Meng F, Liu J, Lu T, et al. SNHG1 knockdown upregulates miR-376a and downregulates FOXK1/Snail axis to prevent tumor growth and metastasis in HCC. Mol Ther Oncolytics, 2021, 21: 264-277.
22. Tan X, Chen WB, Lv DJ, et al. LncRNA SNHG1 and RNA binding protein hnRNPL form a complex and coregulate CDH1 to boost the growth and metastasis of prostate cancer. Cell Death Dis, 2021, 12(2): 138. doi: 10.1038/s41419-021-03413-4.
23. Zhou D, He S, Zhang D, et al. LINC00857 promotes colorectal cancer progression by sponging miR-150-5p and upregulating HMGB3 (high mobility group box 3) expression. Bioengineered, 2021, 12(2): 12107-12122.
24. Zhang W, Ji K, Min C, et al. Oncogenic LINC00857 recruits TFAP2C to elevate FAT1 expression in gastric cancer. Cancer Sci, 2023, 114(1): 63-74.
25. Huang Y, Lin Y, Song X, et al. LINC00857 contributes to proliferation and lymphomagenesis by regulating miR-370-3p/CBX3 axis in diffuse large B-cell lymphoma. Carcinogenesis, 2021, 42(5): 733-741.
26. Ren X, Liu J, Wang R, et al. Exploring the oncogenic roles of LINC00857 in pan-cancer. Front Pharmacol, 2022, 13: 996686. doi: 10.3389/fphar.2022.996686.
27. Chen P, Zeng Z, Wang J, et al. Long noncoding RNA LINC00857 promotes pancreatic cancer proliferation and metastasis by regulating the miR-130b/RHOA axis. Cell Death Discov, 2022, 8(1): 198. doi: 10.1038/s41420-022-01008-2.
28. Li C, Li X, Zhang Y, et al. DSCAM-AS1 promotes cervical carcinoma cell proliferation and invasion via sponging miR-338-3p. Environ Sci Pollut Res Int, 2022, 29(39): 58906-58914.
29. Wang Y, Zhai S, Xing J, et al. Long noncoding RNA DSCAM-AS1 facilitates proliferation and migration of hemangioma endothelial cells by targeting miR-411-5p/TPD52 axis. Biomed Res Int, 2022, 2022: 8696432. doi: 10.1155/2022/8696432.
30. Ghafouri-Fard S, Khoshbakht T, Taheri M, et al. A review on the carcinogenic roles of DSCAM-AS1. Front Cell Dev Biol, 2021, 9: 758513. doi: 10.3389/fcell.2021.758513.
31. Huang X, Wang Z, Hou S, et al. Long non-coding RNA DSCAM-AS1 promotes pancreatic cancer progression via regulating the miR-136-5p/PBX3 axis. Bioengineered, 2022, 13(2): 4153-4165.
32. Liu Y, Shi M, He X, et al. LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma. J Hematol Oncol, 2022, 15(1): 52. doi: 10.1186/s13045-022-01272-w.
33. Ma YS, Yang XL, Liu YS, et al. Long non-coding RNA NORAD promotes pancreatic cancer stem cell proliferation and self-renewal by blocking microRNA-202-5p-mediated ANP32E inhibition. J Transl Med, 2021, 19(1): 400. doi: 10.1186/s12967-021-03052-5.
34. Fang X, Cai Y, Xu Y, et al. Exosome-mediated lncRNA SNHG11 regulates angiogenesis in pancreatic carcinoma through miR-324-3p/VEGFA axis. Cell Biol Int, 2022, 46(1): 106-117.
35. Wu R, Su Z, Zhao L, et al. Extracellular vesicle-loaded oncogenic lncRNA NEAT1 from adipose-derived mesenchymal stem cells confers gemcitabine resistance in pancreatic cancer via miR-491-5p/Snail/SOCS3 axis. Stem Cells Int, 2023, 2023: 6510571. doi: 10.1155/2023/6510571.
36. Liu Y, Luo J, Zeng J, et al. Competing endogenous RNA analysis identified lncRNA DSCR9 as a novel prognostic biomarker associated with metastasis and tumor microenvironment in renal cell carcinoma. Oncol Lett, 2023, 26(1): 290. doi: 10.3892/ol.2023.13876.
37. Li M, Lin C, Cai Z. Downregulation of the long noncoding RNA DSCR9 (Down syndrome critical region 9) delays breast cancer progression by modulating microRNA-504-5p-dependent G protein-coupled receptor 65. Hum Cell. 2023;36(4): 1516-1534.
38. Huang H, Li X, Zhang X, et al. DSCR9/miR-21-5p axis inhibits pancreatic cancer proliferation and resistance to gemcitabine via BTG2 signaling. Acta Biochim Biophys Sin (Shanghai), 2022, 54(12): 1775-1788.
39. Shi Y, Zhang DD, Liu JB, et al. Comprehensive analysis to identify DLEU2L/TAOK1 axis as a prognostic biomarker in hepatocellular carcinoma. Mol Ther Nucleic Acids, 2021, 23: 702-718.
40. Xu F, Wu H, Xiong J, et al. Long non-coding RNA DLEU2L targets miR-210-3p to suppress gemcitabine resistance in pancreatic cancer cells via BRCA2 regulation. Front Mol Biosci, 2021, 8: 645365. doi: 10.3389/fmolb.2021.645365.
41. Guz M, Jeleniewicz W, Cybulski M, et al. Serum miR-210-3p can be used to differentiate between patients with pancreatic ductal adenocarcinoma and chronic pancreatitis. Biomed Rep, 2021, 14(1): 10. doi: 10.3892/br.2020.1386.
42. Yang Z, Zhao N, Cui J, et al. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210. Cell Oncol (Dordr), 2020, 43(1): 123-136.
43. Pan S, Shen M, Zhou M, et al. Long noncoding RNA LINC01111 suppresses pancreatic cancer aggressiveness by regulating DUSP1 expression via microRNA-3924. Cell Death Dis, 2019, 10(12): 883. doi: 10.1038/s41419-019-2123-y.
44. Li K, Han H, Gu W, et al. Long non-coding RNA LINC01963 inhibits progression of pancreatic carcinoma by targeting miR-641/TMEFF2. Biomed Pharmacother, 2020, 129: 110346. doi: 10.1016/j.biopha.2020.110346.
45. Li X, Zhou S, Fan T, et al. LncRNA DGCR 5/miR-27a-3p/BNIP3 promotes cell apoptosis in pancreatic cancer by regulating the p38 MAPK pathway. Int J Mol Med, 2020, 46(2): 729-739.
46. Gao ZQ, Wang JF, Chen DH, et al. Long non-coding RNA GAS5 suppresses pancreatic cancer metastasis through modulating miR-32-5p/PTEN axis. Cell Biosci, 2017, 7: 66. doi: 10.1186/s13578-017-0192-0.
47. Kara G, Calin GA, Ozpolat B. RNAi-based therapeutics and tumor targeted delivery in cancer. Adv Drug Deliv Rev, 2022, 182: 114113. doi: 10.1016/j.addr.2022.114113.
48. Liang Y, Chen X, Wu Y, et al. LncRNA CASC9 promotes esophageal squamous cell carcinoma metastasis through upregulating LAMC2 expression by interacting with the CREB-binding protein. Cell Death Differ, 2018, 25(11): 1980-1995.
49. Vaidya AM, Sun Z, Ayat N, et al. Systemic delivery of tumor-targeting siRNA nanoparticles against an oncogenic lncRNA facilitates effective triple-negative breast cancer therapy. Bioconjug Chem, 2019, 30(3): 907-919.
50. Pang H, Ren Y, Li H, et al. LncRNAs linc00311 and AK141205 are identified as new regulators in STAT3-mediated neuropathic pain in bCCI rats. Eur J Pharmacol, 2020, 868: 172880. doi: 10.1016/j.ejphar.2019.172880.
51. Xu L, Wei B, Hui H, et al. Positive feedback loop of lncRNA LINC01296/miR-598/Twist1 promotes non-small cell lung cancer tumorigenesis. J Cell Physiol, 2019, 234(4): 4563-4571.
52. Schultheis B, Strumberg D, Kuhlmann J, et al. Safety, efficacy and pharcacokinetics of targeted therapy with the liposomal RNA interference therapeutic Atu027 combined with gemcitabine in patients with pancreatic adenocarcinoma. A randomized phase Ⅰb/Ⅱa study. Cancers (Basel), 2020, 12(11): 3130. doi: 10.3390/cancers12113130.
53. Zorde-Khvalevsky E, Gabai R, Rachmut IH, et al. Mutant KRAS is a druggable target for pancreatic cancer. Proc Natl Acad Sci USA, 2013, 110(51): 20723-20728.
54. Adams D, Polydefkis M, González-Duarte A, et al. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurol, 2021, 20(1): 49-59.
55. Balwani M, Sardh E, Ventura P, et al. Phase 3 Trial of RNAi therapeutic givosiran for acute intermittent porphyria. N Engl J Med, 2020, 382(24): 2289-2301.
56. Crooke ST, Baker BF, Crooke RM, et al. Antisense technology: an overview and prospectus. Nat Rev Drug Discov, 2021, 20(6): 427-453.
57. Arun G, Diermeier S, Akerman M, et al. Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss. Genes Dev, 2016, 30(1): 34-51.
58. Taiana E, Favasuli V, Ronchetti D, et al. Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma. Leukemia, 2020, 34(1): 234-244.
59. Sutaria DS, Jiang J, Azevedo-Pouly ACP, et al. Expression profiling identifies the noncoding processed transcript of HNRNPU with proliferative properties in pancreatic ductal adenocarcinoma. Noncoding RNA, 2017, 3(3): 24. doi: 10.3390/ncrna3030024.
60. Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. Science, 2013, 339(6121): 819-823.
61. Mali P, Yang L, Esvelt KM, et al. RNA-guided human genome engineering via Cas9. Science, 2013, 339(6121): 823-826.
62. Chen Y, Li Z, Chen X, et al. Long non-coding RNAs: from disease code to drug role. Acta Pharm Sin B, 2021, 11(2): 340-354.
63. Dorn A, Glaß M, Neu CT, et al. LINC00261 is differentially expressed in pancreatic cancer subtypes and regulates a pro-epithelial cell identity. Cancers (Basel), 2020, 12(5): 1227. doi: 10.3390/cancers12051227.
64. Guo R, Su Y, Zhang Q, et al. LINC00478-derived novel cytoplasmic lncRNA LacRNA stabilizes PHB2 and suppresses breast cancer metastasis via repressing MYC targets. J Transl Med, 2023, 21(1): 120. doi: 10.1186/s12967-023-03967-1.
65. Chang KW, Hung WW, Chou CH, et al. LncRNA MIR31HG drives oncogenicity by inhibiting the limb-bud and heart development gene ( LBH) during oral carcinoma. Int J Mol Sci, 2021, 22(16): 8383. doi: 10.3390/ijms22168383.
66. Boos F, Oo JA, Warwick T, et al. The endothelial-enriched lncRNA LINC00607 mediates angiogenic function. Basic Res Cardiol, 2023, 118(1): 5. doi: 10.1007/s00395-023-00978-3.
67. Goyal A, Myacheva K, Groß M, et al. Challenges of CRISPR/Cas9 applications for long non-coding RNA genes. Nucleic Acids Res, 2017, 45(3): e12. doi: 10.1093/nar/gkw883.
68. Ren Y, Wang YF, Zhang J, et al. Targeted design and identification of AC1NOD4Q to block activity of HOTAIR by abrogating the scaffold interaction with EZH2. Clin Epigenetics, 2019, 11(1): 29. doi: 10.1186/s13148-019-0624-2.
69. Ji D, Hou L, Xie C, et al. Deoxyelephantopin suppresses pancreatic cancer progression in vitro and in vivo by targeting linc00511/miR-370-5p/p21 promoter axis. J Oncol, 2022, 2022: 3855462. doi: 10.1155/2022/3855462.
70. Matouk I, Raveh E, Ohana P, et al. The increasing complexity of the oncofetal H19 gene locus: functional dissection and therapeutic intervention. Int J Mol Sci, 2013, 14(2): 4298-4316.
71. Gofrit ON, Benjamin S, Halachmi S, et al. DNA based therapy with diphtheria toxin-A BC-819: a phase 2b marker lesion trial in patients with intermediate risk nonmuscle invasive bladder cancer. J Urol, 2014, 191(6): 1697-1702.
72. Lavie O, Edelman D, Levy T, et al. A phase 1/2a, dose-escalation, safety, pharmacokinetic, and preliminary efficacy study of intraperitoneal administration of BC-819 (H19-DTA) in subjects with recurrent ovarian/peritoneal cancer. Arch Gynecol Obstet, 2017, 295(3): 751-761.
73. Hanna N, Ohana P, Konikoff FM, et al. Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of BC-819 in patients with unresectable pancreatic cancer. Cancer Gene Ther, 2012, 19(6): 374-381.

Previous Article
乳腺癌广泛腹腔转移误诊急性阑尾炎1例报道
Next Article
Application and progress of common autologous organ transplantation techniques

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Research progress of long non-coding RNA as competitive endogenous RNA and its targeting technology in pancreatic cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content